Did CEOs and officers buy or sell their own stock?
Open-market trades by the people who know the company best, with their own money.
Last 7 days: the stocks insiders bought and sold most
Stocks Koreans hold most · disclosed Last 7 days · open-market trades only
Bought most
Sold most
Whalegun
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Gyre TherapeuticsGYRE | Open-market sale | 06/09–06/18 | 06/22 | 11,000 sh3 trades | $6.25avg. | $68,700 | −1.5% | |
Weiguo YeCOO | Gyre TherapeuticsGYRE | Open-market sale | 06/11 | 06/15 | 2,800 sh | $6.17 | $17,276 | −0.4% |
Gyre TherapeuticsGYRE | Open-market sale | 06/09–06/10 | 06/11 | 20,918 sh2 trades | $6.16avg. | $128,885.78 | −2.9% | |
Gyre TherapeuticsGYRE | Open-market sale | 06/04–06/05 | 06/08 | 34,976 sh2 trades | $6.25avg. | $218,561.15 | −4.8% | |
Gyre TherapeuticsGYRE | Open-market sale | 05/22–05/26 | 05/27 | 7,500 sh2 trades | $6.09avg. | $45,680 | −1.1% | |
Gyre TherapeuticsGYRE | Open-market sale | 05/20–05/21 | 05/22 | 22,220 sh2 trades | $6.15avg. | $136,653 | −3.1% | |
Gyre TherapeuticsGYRE | Open-market sale | 05/18–05/19 | 05/20 | 9,320 sh2 trades | $6.38avg. | $59,418.4 | −1.3% | |
Gyre TherapeuticsGYRE | Open-market sale | 05/14–05/15 | 05/18 | 28,680 sh2 trades | $6.79avg. | $194,772.8 | −3.9% | |
Gyre TherapeuticsGYRE | Open-market sale10b5-1 plan | 05/05–05/06 | 05/07 | 10,315 sh2 trades | $8.04avg. | $82,927.23 | −0.4% | |
Gyre TherapeuticsGYRE | Open-market sale10b5-1 plan | 25/05/27–25/05/28 | 25/05/29 | 2,558 sh2 trades | $10.23avg. | $26,179.06 | −0.1% | |
Gyre TherapeuticsGYRE | Open-market sale10b5-1 plan | 25/05/22–25/05/23 | 25/05/27 | 2,182 sh2 trades | $10.91avg. | $23,803.68 | −0.1% | |
Gyre TherapeuticsGYRE | Open-market sale10b5-1 plan | 25/05/20–25/05/21 | 25/05/22 | 4,000 sh2 trades | $11.04avg. | $44,160 | −0.1% | |
Gyre TherapeuticsGYRE | Open-market sale10b5-1 plan | 25/05/16–25/05/19 | 25/05/20 | 4,000 sh2 trades | $11.21avg. | $44,840 | −0.1% | |
Gyre TherapeuticsGYRE | Open-market sale10b5-1 plan | 25/05/14–25/05/15 | 25/05/16 | 2,020 sh2 trades | $10.69avg. | $21,586 | −0.1% | |
Gyre TherapeuticsGYRE | Open-market sale10b5-1 plan | 25/05/12–25/05/13 | 25/05/14 | 4,000 sh2 trades | $10.97avg. | $43,860 | −0.1% | |
Songjiang MaPresident | Gyre TherapeuticsGYRE | Open-market sale10b5-1 plan | 25/03/21 | 25/03/25 | 174 sh | $10.00 | $1,740 | −0.0% |
Gyre TherapeuticsGYRE | Open-market sale10b5-1 plan | 25/03/19–25/03/20 | 25/03/21 | 4,000 sh2 trades | $10.11avg. | $40,440 | −0.1% | |
Gyre TherapeuticsGYRE | Open-market sale10b5-1 plan | 25/03/17–25/03/18 | 25/03/19 | 2,242 sh2 trades | $11.89avg. | $26,658.08 | −0.1% | |
Gyre TherapeuticsGYRE | Open-market sale10b5-1 plan | 25/03/13–25/03/14 | 25/03/17 | 4,000 sh2 trades | $12.06avg. | $48,220 | −0.1% | |
Gyre TherapeuticsGYRE | Open-market sale10b5-1 plan | 25/03/11–25/03/12 | 25/03/13 | 4,000 sh2 trades | $11.57avg. | $46,280 | −0.1% |